Skip to search formSkip to main contentSkip to account menu

SU 11654

Known as: SU-11654, SU11654 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

toceranib phosphate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Abstract SY28-01: Spontaneous cancer in dogs: Opportunities for preclinical evaluation of novel therapies
Spontaneous cancers are common in the pet dog population with estimated 60% of dogs that live to 10 years of age developing… 
2010
2010
Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Toceranib phosphate (Palladia, SU11654), an oral tyrosine-kinase inhibitor, is under investigation for the treatment of mast cell… 
Review
2010
Review
2010
Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs.
Toceranib phosphate (Palladia, SU11654), a multireceptor tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity… 
Review
2010
Review
2010
Abstract IA5-1: Spontaneous cancer in dogs: Opportunities for preclinical investigation of novel therapeutics
Spontaneous cancers occur commonly in the pet dog population. Indeed, an estimated 60% of dogs that live to 10 years of age will… 
2009
2009
Catching Cancer by theTail: New Perspectives on the Use of
In this issue of Clinical Cancer Research , London and colleagues report on the evaluation of a small molecule multiple-targeted… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)